



25 July 2024

Circular 011/24

RE: Cariban® (doxylamine/pyridoxine)

Dear Pharmacist,

I refer to the arrangements put in place for supply of the Exempt Medicinal Product (EMP), Cariban® (doxylamine/pyridoxine) on 1 January 2023 (Ref: Circular 001/23).

The licensed Cariban® product recently underwent formal pricing and reimbursement assessment following an application from the Marketing Authorisation Holder to the HSE and has been approved for reimbursement under Community Drug Schemes. Therefore, PCRS will be standing down the exceptional arrangement for the unlicensed product.

From 1 August 2024, Cariban® will be available on the Reimbursement List and can be claimed in the normal manner under Community Drug Schemes (i.e. GMS and DPS) on foot of a valid prescription from a prescriber. There will be no managed access arrangement in place for the licensed product and it will not be restricted to consultant prescribing/initiation. However, PCRS will continue to audit/monitor usage.

PCRS will facilitate claims of the EMP for approved patients under the old arrangement for one month (August 2024) to enable any existing EMP stock to be exhausted. Please note that retrospective claims (January 2023 – July 2024) for those who did not have patient specific approval in place for Cariban® will not be paid.

The reimbursement details for Cariban® with effect from 1 August 2024 is as follows:

Reimbursement Code	Drug Name	Pack Size	Pharmaceutical Form	Reimbursement Price
67209	Cariban 10mg/10mg modified release	24	hard capsules	€13.60

Yours faithfully,

Shaun Flanagan
Assistant National Director
Primary Care Reimbursement Service